The relationship between catechol-O-methyltransferase (COMT) polymorphisms and the development of breast cancer

Yu Fan, Yumei Feng, Limei Wang, Ying Wang, Li Fu

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objective: To investigate the relationship between COMT genetic polymorphisms and the development and prognosis of breast cancer. Methods: A G/A (Val/Met) polymorphism in codon 158 in exon 4 of COMT was analyzed using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) in 200 cases with breast cancer and 100 samples of normal breast tissue. The expression of ER, PR, p53 and CerbB-2 was detected in the samples using immunohistochemistry. The difference in genotypic distribution frequency between the groups, the correlation between the genotypes and the factors related to prognosis were analyzed. Results: The incidence of homozygous and variant genotypes in breast cancer was significantly higher than in the controls (P=0.0267). The proportion of variant genotype increased as clinical stage (P=0.0082) and histological grades (P=0.0146) advanced, as well as with increased numbers of lymph node metastases (P=0.0387). In the ER positive group, there was a more significant correlation between the COMT genotypes and the clinical stage (P=0.0004), histological stages (P=0.0116) and lymph node metastasis (P=0.0008). Conclusion: The variant genotype (Met/Met) is associated with breast cancer risk. In patients with breast cancer there is a correlation between the low activity COMT allele (COMT-LL and COMT-HL) and some factors indicating poor prognosis, including more lymph node metastases as well as a more advanced clinical stage and histological grouping.

Original languageEnglish (US)
Pages (from-to)430-433
Number of pages4
JournalChinese Journal of Clinical Oncology
Volume34
Issue number8
StatePublished - Dec 1 2007

Fingerprint

Catechol O-Methyltransferase
Breast Neoplasms
Genotype
Lymph Nodes
Neoplasm Metastasis
Genetic Polymorphisms
Codon
Restriction Fragment Length Polymorphisms
Exons
Breast
Immunohistochemistry
Alleles
Polymerase Chain Reaction
Incidence

Keywords

  • Breast
  • COMT
  • Cancer
  • Development
  • Genetic
  • Polymorphisms
  • Prognosis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

The relationship between catechol-O-methyltransferase (COMT) polymorphisms and the development of breast cancer. / Fan, Yu; Feng, Yumei; Wang, Limei; Wang, Ying; Fu, Li.

In: Chinese Journal of Clinical Oncology, Vol. 34, No. 8, 01.12.2007, p. 430-433.

Research output: Contribution to journalArticle

@article{0b6ce675161f4a6c83728540f37b5c1b,
title = "The relationship between catechol-O-methyltransferase (COMT) polymorphisms and the development of breast cancer",
abstract = "Objective: To investigate the relationship between COMT genetic polymorphisms and the development and prognosis of breast cancer. Methods: A G/A (Val/Met) polymorphism in codon 158 in exon 4 of COMT was analyzed using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) in 200 cases with breast cancer and 100 samples of normal breast tissue. The expression of ER, PR, p53 and CerbB-2 was detected in the samples using immunohistochemistry. The difference in genotypic distribution frequency between the groups, the correlation between the genotypes and the factors related to prognosis were analyzed. Results: The incidence of homozygous and variant genotypes in breast cancer was significantly higher than in the controls (P=0.0267). The proportion of variant genotype increased as clinical stage (P=0.0082) and histological grades (P=0.0146) advanced, as well as with increased numbers of lymph node metastases (P=0.0387). In the ER positive group, there was a more significant correlation between the COMT genotypes and the clinical stage (P=0.0004), histological stages (P=0.0116) and lymph node metastasis (P=0.0008). Conclusion: The variant genotype (Met/Met) is associated with breast cancer risk. In patients with breast cancer there is a correlation between the low activity COMT allele (COMT-LL and COMT-HL) and some factors indicating poor prognosis, including more lymph node metastases as well as a more advanced clinical stage and histological grouping.",
keywords = "Breast, COMT, Cancer, Development, Genetic, Polymorphisms, Prognosis",
author = "Yu Fan and Yumei Feng and Limei Wang and Ying Wang and Li Fu",
year = "2007",
month = "12",
day = "1",
language = "English (US)",
volume = "34",
pages = "430--433",
journal = "Chinese Journal of Clinical Oncology",
issn = "1000-8179",
publisher = "China Anti-Cancer Association",
number = "8",

}

TY - JOUR

T1 - The relationship between catechol-O-methyltransferase (COMT) polymorphisms and the development of breast cancer

AU - Fan, Yu

AU - Feng, Yumei

AU - Wang, Limei

AU - Wang, Ying

AU - Fu, Li

PY - 2007/12/1

Y1 - 2007/12/1

N2 - Objective: To investigate the relationship between COMT genetic polymorphisms and the development and prognosis of breast cancer. Methods: A G/A (Val/Met) polymorphism in codon 158 in exon 4 of COMT was analyzed using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) in 200 cases with breast cancer and 100 samples of normal breast tissue. The expression of ER, PR, p53 and CerbB-2 was detected in the samples using immunohistochemistry. The difference in genotypic distribution frequency between the groups, the correlation between the genotypes and the factors related to prognosis were analyzed. Results: The incidence of homozygous and variant genotypes in breast cancer was significantly higher than in the controls (P=0.0267). The proportion of variant genotype increased as clinical stage (P=0.0082) and histological grades (P=0.0146) advanced, as well as with increased numbers of lymph node metastases (P=0.0387). In the ER positive group, there was a more significant correlation between the COMT genotypes and the clinical stage (P=0.0004), histological stages (P=0.0116) and lymph node metastasis (P=0.0008). Conclusion: The variant genotype (Met/Met) is associated with breast cancer risk. In patients with breast cancer there is a correlation between the low activity COMT allele (COMT-LL and COMT-HL) and some factors indicating poor prognosis, including more lymph node metastases as well as a more advanced clinical stage and histological grouping.

AB - Objective: To investigate the relationship between COMT genetic polymorphisms and the development and prognosis of breast cancer. Methods: A G/A (Val/Met) polymorphism in codon 158 in exon 4 of COMT was analyzed using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) in 200 cases with breast cancer and 100 samples of normal breast tissue. The expression of ER, PR, p53 and CerbB-2 was detected in the samples using immunohistochemistry. The difference in genotypic distribution frequency between the groups, the correlation between the genotypes and the factors related to prognosis were analyzed. Results: The incidence of homozygous and variant genotypes in breast cancer was significantly higher than in the controls (P=0.0267). The proportion of variant genotype increased as clinical stage (P=0.0082) and histological grades (P=0.0146) advanced, as well as with increased numbers of lymph node metastases (P=0.0387). In the ER positive group, there was a more significant correlation between the COMT genotypes and the clinical stage (P=0.0004), histological stages (P=0.0116) and lymph node metastasis (P=0.0008). Conclusion: The variant genotype (Met/Met) is associated with breast cancer risk. In patients with breast cancer there is a correlation between the low activity COMT allele (COMT-LL and COMT-HL) and some factors indicating poor prognosis, including more lymph node metastases as well as a more advanced clinical stage and histological grouping.

KW - Breast

KW - COMT

KW - Cancer

KW - Development

KW - Genetic

KW - Polymorphisms

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=84865055030&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865055030&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84865055030

VL - 34

SP - 430

EP - 433

JO - Chinese Journal of Clinical Oncology

JF - Chinese Journal of Clinical Oncology

SN - 1000-8179

IS - 8

ER -